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Motor Axon Synapses on Renshaw Cells Contain Higher
Levels of Aspartate than Glutamate
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Abstract
Motoneuron synapses on spinal cord interneurons known as Renshaw cells activate nicotinic, AMPA and NMDA receptors
consistent with co-release of acetylcholine and excitatory amino acids (EAA). However, whether these synapses express
vesicular glutamate transporters (VGLUTs) capable of accumulating glutamate into synaptic vesicles is controversial. An
alternative possibility is that these synapses release other EAAs, like aspartate, not dependent on VGLUTs. To clarify the
exact EAA concentrated at motor axon synapses we performed a quantitative postembedding colloidal gold
immunoelectron analysis for aspartate and glutamate on motor axon synapses (identified by immunoreactivity to the
vesicular acetylcholine transporter; VAChT) contacting calbindin-immunoreactive (-IR) Renshaw cell dendrites. The results
show that 71% to 80% of motor axon synaptic boutons on Renshaw cells contained aspartate immunolabeling two
standard deviations above average neuropil labeling. Moreover, VAChT-IR synapses on Renshaw cells contained, on
average, aspartate immunolabeling at 2.5 to 2.8 times above the average neuropil level. In contrast, glutamate enrichment
was lower; 21% to 44% of VAChT-IR synapses showed glutamate-IR two standard deviations above average neuropil
labeling and average glutamate immunogold density was 1.7 to 2.0 times the neuropil level. The results were not influenced
by antibody affinities because glutamate antibodies detected glutamate-enriched brain homogenates more efficiently than
aspartate antibodies detecting aspartate-enriched brain homogenates. Furthermore, synaptic boutons with ultrastructural
features of Type I excitatory synapses were always labeled by glutamate antibodies at higher density than motor axon
synapses. We conclude that motor axon synapses co-express aspartate and glutamate, but aspartate is concentrated at
higher levels than glutamate.
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Introduction
The release of acetylcholine from motor axons at the
mammalian neuromuscular junction (NMJ) has been established
for more than 75 years [1], but recent studies suggest that
additional neurotransmitters, in particular excitatory amino acids
(EAAs) like glutamate, might be co-released from motoneuron
synapses both in the periphery and centrally. High levels of
glutamate, EAA transporters and AMPA/NMDA receptors have
been detected in motor end-plates [2–4] and significant actions of
glutamate receptors on NMJ cholinergic neurotransmission have
been described. For example, activation of presynaptic metabo-
tropic glutamate receptors modulates acetylcholine neurotrans-
mitter release at the NMJ [5,6] and postsynaptic NMDA receptor-
mediated nitric oxide release regulates acetylcholinesterase activity
[7]. However, motor axon postsynaptic actions on normal
mammalian muscles are fully blocked by nicotinic acetylcholine
receptor antagonists and a contribution from NMDA/AMPA
receptors to postsynaptic end-plate currents is not commonly
observed. Nevertheless, NMDA/AMPA receptor responses can be
induced experimentally after muscle dennervation and re-inner-
vation with glutamatergic axons [8,9].
Motoneuron axons also extend collaterals inside the spinal cord
and establish synapses with Renshaw cells, an interneuron that
provides feedback inhibition to the same motoneurons [10,11].
Similar to the NMJ, motor axon actions on Renshaw cells were
also found to be cholinergic at first [10,12], a finding that, at the
time, confirmed Dale’s principle for the equivalence of neuro-
transmitter release in all synaptic boutons from single axons
(Eccles, 1976). Acetylcholine receptor antagonists, however, did
not fully inhibit the postsynaptic actions of motor axons on
Renshaw cells. In the original studies it was argued that this was
due to relatively low concentrations of antagonists inside synaptic
clefts during in vivo pharmacological experiments [10,12]. Later, in
vitro studies (spinal cord slices or whole neonatal spinal cords) also
failed to fully inhibit Renshaw cell-mediated disynaptic recurrent
inhibition of motoneurons or motor axon excitatory postsynaptic
currents (EPSCs) on Renshaw cells with acetylcholine [13,14]. In
this case receptor antagonists were bath applied to either isolated
spinal cords or spinal cord slices, an experimental situation
believed to result in better saturation of postsynaptic receptors by
antagonists. More recent analyses in neonatal mouse in vitro spinal
cord preparations demonstrated that motor axon evoked EPSPs
and EPSCs on Renshaw cells display various components
mediated respectively by nicotinic, NMDA and AMPA receptors
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[15–18] and that, similar to the NMJ, glutamate-immunoreactivity
is enriched in motor axon synapses on Renshaw cells [17]. The
presence of significant NMDA receptor postsynaptic currents
could explain the relatively longer time course of motor axon
synaptic actions on Renshaw cells compared to muscle, a fact that
puzzled investigators since it was first described [10,19]. Further-
more, late Renshaw cell discharges in response to motor axon
input were shown to be NMDA-dependent in the neonatal spinal
cord [15].
Despite these advances, the exact mechanisms used by motor
axons to co-release acetylcholine and possibly glutamate remained
unclear. Most studies agree that vesicular glutamate transporters
(VGLUTs) are not co-localized with vesicular acetylcholine
transporters (VAChT) at motor axon synapses contacting
Renshaw cells [17,18,20,21]. Two studies using intracellular fills
of single motor axons in neonates raised the possibility that,
contrary to Dale’s principle, motor axons could traffic VGLUTs
(specifically VGLUT2) and VAChT to different axon collaterals
and thus release different neurotransmitters at different synapses
[18,20], however, this could not be confirmed in other studies
using similar methods in adult cats [21] or using bulk labeling of
motor axons from ventral roots in neonatal rodent spinal cords
[17]. Whether motoneurons express VGLUT2 is also controver-
sial. Some in situ hybridization studies detected VGLUT2 mRNA
in motoneurons [18,20,22], but others did not [23–25]. Given that
VGLUT expression is necessary for the synaptic release of
glutamate [26–28], it is of concern that VGLUTs cannot be
consistently demonstrated in motoneurons or their synapses. One
possibility is that motoneurons express very low levels of
VGLUT2, perhaps close to the threshold for detection. This
would explain the disparity of results using more or less stringent
labeling conditions or criteria. But, given the relationship between
VGLUT2 expression levels, vesicular glutamate concentration and
postsynaptic action [29], it is difficult to reconcile low levels of
VGLUT2 with consistent motor axon activation of NMDA
receptors on Renshaw cells.
One alternative possibility is that other compounds capable of
activating NMDA and/or AMPA receptors are released from the
motor axons through VGLUT-independent mechanisms. One
possibility is that these synapses are in part aspartaergic. Aspartate
has similar affinity for NMDA receptors as glutamate and
generates similar NMDA currents [30], but its transport into
synaptic vesicles is independent of VGLUTs [26,31–34]. To
clarify the exact EAA content of motor axon synapses on Renshaw
cells we analyzed their relative enrichment in glutamate and
aspartate. Because the large majority (.80%) of VAChT-
immunoreactive (-IR) synapses on Renshaw cells originate from
motor axons and few (,5%) from other sources [35], we identified
motor axon synapses with dual preembedding immunolabeling to
detect VAChT-IR synapses (using immunogold silver) on
calbindin-IR Renshaw cell dendrites (identified with immunoper-
oxidase). These dual imunolabeled sections were then tested for
glutamate or aspartate content using postembedding colloidal
immunogold methods. Quantification of these electron microsco-
py triple immuolabeled preparations suggested that aspartate is
more highly and consistently enriched than glutamate in motor
axon terminals on Renshaw cells.
Materials and Methods
Animals
All animal procedures were done in accordance with Wright
State University’s Laboratory Animal Use Committee and NIH
guidelines and were approved by Wright State University
Institutional Animal Care and Use Committee (IACUC) commit-
tee. For electron microscopy, C57/bl mice were anesthetized with
pentobarbital (Euthasol 50–70 mg/kg i.p.) and perfused transcar-
dially, first with a cold vascular rinse (0.01 M phosphate buffer
with 137 mM NaCl, 3.4 mM KCl, and 6 mM NaHCO3, pH 7.3)
followed by 2.5% glutaraldehyde (Electron Microscopy Sciences,
Hatfield, PA) and 1.0% paraformaldehyde in 0.1 M phosphate
buffer (PB). The spinal cords were then removed, post-fixed in the
same fixative for 4 hours and cut in 100 mm thick vibratome
sections.
Pre-embedding electron microscopy immunolabeling for
calbindin and VAChT
The sections were pretreated with 1% NaBH4 (Sigma-Aldrich,
St. Louis, MO) in PBS and blocked for 30 minutes in 10% normal
donkey serum (Jackson ImmunoResearch, West Grove, PA)
diluted in PBS and then incubated in a goat anti-VAChT
polyclonal antibody (Millipore, Temecula, CA; cat. number:
AB1578, lot: 602021588) diluted 1:1,000 in PBS overnight at
room temperature. Sections were then incubated in a biotinylated-
SP anti-goat secondary antibody (Jackson Immunoresearch)
diluted 1:100 and then in streptavidin coupled to 1.4 nm gold
particles (Nanoprobes, Yaphank, NY) at a 1:50 dilution (both in
PBS). The tissue was treated with 50 mM glycine in PBS and
bovine serum albumin at 1.0% (Sigma-Aldrich) in PBS and then
rinsed briefly in nano-distilled H2O (ndH2O) before silver
intensification with an HQ Silver Enhancement Kit (Nanoprobes).
Developing reactions to generate silver particles on VAChT-
immunoreactive (-IR) sites lasted from 2 to10 minutes. The silver
reaction product was stabilized with 0.05% gold chloride solution
followed by rinses in 0.2 M tris maleate buffer and a brief
incubation in 3% sodium thiosulfate solution to dissolve any
remaining unbound silver. Following these rinses the tissue
sections were again incubated overnight in a new primary
antibody solution containing rabbit anti-calbindin (Swant, Bellin-
zona, Switzerland; cat. number: CB-38a, lot: 9.03), diluted 1:500
in PBS to label Renshaw cells and their processes. To reveal
calbindin-immunoreactivity we used anti-rabbit ABC-peroxidase
standard Vector kits (Vector Labs Inc., Burlingame, CA).
Peroxidase-labeled immunoreactive sites were revealed with
0.02% diaminobenzidine (DAB) and 0.01% hydrogen peroxide
in PBS. The reactions were carried out for 5–10 minutes at room
temperature.
Cryosubstitution and Lowicryl embedding
Immunolabeled sections were cryoprotected in an ascending
series of glycerol solutions diluted in 0.1 M PB (30 minute
incubations at 10%, 20%, and 30% strength), followed by
overnight incubation in 30% glycerol. The following day the
sections were freeze-slammed using the ‘‘copper-mirror’’ tech-
nique in a Leica MM80 apparatus. The frozen sections were then
placed at -80uC in a cryosubstitution chamber and rinsed 4 times
in methanol for 30 minutes each. This was followed by an
ascending series of methanol:Lowicryl solutions at 250uC and two
changes into fresh 100% Lowicryl where it remained overnight.
The tissue was flat-embedded between teflon-coated glass cover-
slips and placed under ultraviolet light for resin polymerization at
the following temperature schedule: 250uC for 49 hours, raised to
0uC over a time of 5 hours, held at 0uC for 72 hours, raised to
20uC over a time of 10 hours, followed by a 24 hours at 20uC.
Motor Axon Aspartate and Glutamate Content
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Colloidal gold post-embedding with aspartate and
glutamate antibodies
Areas of interest containing calbindin-IR Renshaw cells were
identified under the light microscope in flat-embedded section
wafers and then cut out and placed on EM beam resin capsules for
ultramicrotomy. Ultrathin sections (,70–90 nm thick, gold-silver
interference contrast) were obtained and collected on 200 mesh
nickel grids coated with Formvar (Electron Microscopy Sciences).
The grids were then processed for postembedding colloidal gold
immunostaining. First, they were pre-incubated in 10% normal
goat serum (Vector) and then incubated overnight at 4uC in a
primary antibody solution containing either rabbit anti-glutamate
(0.17 mg/ml & 0.034 mg/ml, Alpha Diagnostics International, San
Antonio, TX; Cat.#: GLM21-S, lot:40128S) or rabbit anti-
aspartate (0.36 mg/ml and 0.18 mg/ml, Biogenesis Ltd., Poole,
UK; Cat. number 0770-0004, lot:A980421) diluted in Tris Buffer
Saline with 0.05% Tween (TBS-Tw) at a pH of 7.6. The next day
the grids were rinsed in TBS-Tw pH 7.6 followed by a rinse in
TBS-Tw pH 8.2 and incubated in a secondary antibody solution
containing anti-rabbit antibodies conjugated to 10 nm colloidal
gold particles (British BioCell International (BBI), Cardiff, UK) at
1:25 dilution in TBS-Tw pH 8.2 for 2 hours. Following this
incubation, grids were rinsed in nanopure distilled water (ndH2O)
and the ultrathin sections were then contrasted using 1% uranyl
acetate solution and standard Reynold’s lead citrate solution.
Electron microscopy image capturing and analysis
Contrasted and immunolabeled ultrathin sections were exam-
ined in a Phillips 208S electron microscope at 70 kV. Images were
obtained photographically (EM 465 negatives) and the negatives
scanned at 1200 dpi (Flextight 848; Imacom, Copenhagen,
Denmark). Micrographs were obtained from 4 to 6 ultrathin
sections from different regions in the Renshaw area in each of
three different mice analyzed. Scanned images containing
VAChT-IR boutons were identified by their immunogold
immunoreactivity and classified as belonging to motor axons if
they established a synapse on a calbindin-IR Renshaw cell soma or
dendrite or classified as a C-bouton (originated in cholinergic
interneurons) if the synapse was on a motoneuron cell body and
displayed a submembrane cistern [36]. Other VAChT-IR
terminals in the neuropil have more uncertain origins and were
not included in the analyses.
Quantitative analyses were carried out using Image Pro Plus
(ver. 5.1; Media Cybernetics, Silver Spring, MD). The area of
axoplasm from which neurotransmitters could be loaded into
synaptic vesicles was determined by measuring the area of the
bouton and subtracting the area occupied by mitochondria. Then
the number of colloidal gold particles inside the bouton, but
outside mitochondria, was counted and a density calculated
(number of gold particles per 1 mm2). Average densities of gold
particles were estimated for each animal or the whole sample of
VAChT-IR boutons contacting calbindin-IR Renshaw cells
dendrites and VAChT-IR boutons contacting motoneurons
(mostly C-boutons). To determine if there was immunogold
enrichment inside VAChT-IR boutons above average neuropil
staining, 1 mm2 regions of interest (ROIs) were similarly analyzed
in the neuropil. Neuropil ROIs were collected from the regions at
the four corners of the scanned negatives. Similar to the boutons,
areas associated with mitochondria and their associated gold
particles were subtracted from the density calculation. Any
neuropil test squares covering areas of the photograph that
contained VAChT-IR synapses, artifacts or grid bars were
excluded.
Statistical comparisons
When possible paired groups of data were compared using
standard t-tests and multiple groups with standard one-way
ANOVA followed by pair-wise comparisons among the groups
using a Tukey test. However, data were frequently not normally
distributed. This was usually the case in samples with low levels of
immunolabeling and skewed data points or in samples with several
estimates at zero. In these cases we used non-parametric tests:
Mann-Whitney Rank-Sum test for comparing two groups and
Kruskal-Wallis ANOVA on Ranks for more than two groups
followed by post-hoc Dunn’s test for pair-wise comparisons.
Statistical significance was set at p,0.05. All statistics were run in
Sigma-Stat 3.1 (Jandel Corporation, Chicago, IL).
Antibody specificity
Aspartate and glutamate antibodies. The rabbit aspartate
polyclonal antibody (Biogenesis) was raised against a glutaralde-
hyde conjugate of aspartate and bovine thyroglobulin while the
rabbit glutamate polyclonal antibody (Alpha Diagnostics Interna-
tional) was raised against a glutaraldehyde conjugate of glutamate
and hemocyanin. The specificity of the antibodies was tested
against various glutaraldehyde fixed amino acids using resin
sandwiches kindly provided by Dr. O. P. Ottersen (University of
Oslo, Norway). The production of test sandwiches is described
elsewhere [37]. Layers with brain sections were separated by layers
of brain homogenate ‘‘islands’’ contained the following glutaral-
dehyde-fixed amino acids: aspartate, GABA, glutamate, gluta-
mine, glycine, taurine, and no amino acids (Fig. 1). Electron
microscopy grids containing these test sections were immunola-
beled with colloidal gold particles as described above. High
magnification images (100,000x) were taken of the amino acid
enriched brain homogenate ‘‘islands’’ with a digital camera
coupled to the electron microscope (Gatan, Bio Scan II,
Pleasonton, CA) and the density of gold particles calculated.
Calbindin antibodies. The rabbit polyclonal antibody used
in electron microscopy experiments was raised against rat
recombinant calbindin D28k and detects a single 28 kDa band
in western blots of brain homogenates of tissue originating from
several species including rat, rabbit, guinea pig, mouse, chicken
and zebrafish (information provided by manufacturer: Swant,
Bellinzona, Switzerland), it does not stain any structures in the
spinal cord of calbindin-D28k knockout mice (Valerie C. Siembab
and Francisco J. Alvarez, unpublished) and immunostains the
same Renshaw cells detected with in situ hybridization for
calbindin mRNA transcript [38]. In dual immunofluorescence
preparations between this polyclonal calbindin antibody and a
monoclonal antibody produced by hybridization of myeloma cells
with spleen cells from mice immunized with calbindin D28K
purified from chicken gut [39], both antibodies labeled the same
cells (not shown).
VAChT antibody. We used a polyclonal antibody raised in
goat against amino acids 511–530 in the C-terminus of rat
VAChT (Millipore, cat. no. AB1588; lot#848850). This antibody
revealed the same VAChT expressing spinal cord cells detected
with in situ hybridization [38]. At the ultrastructural level VAChT-
IR boutons on motoneurons display the morphological features of
cholinergic C-boutons [36], (also see results) and VAChT-
immunoreactivity using these antibodies also detected specifically
synaptic varicosities on Renshaw cells originated from motor
axons retrogradely labeled from the ventral root [17].
Motor Axon Aspartate and Glutamate Content
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Results
Specificity of polyclonal aspartate and glutamate
antibodies
Specificity was determined on layers of brain homogenates
containing various glutaraldehyde-fixed amino acids (aspartate,
GABA, glutamate, glycine and taurine) or no amino acid. Brain
homogenate particles (‘‘islands’’) enriched with the different amino
acids were sandwiched in between layers of brain tissue (Fig. 1A)
and immunolabeleld with aspartate or glutamate antibodies in
post-embedding (Figs. 1B–K). Two different antibody concentra-
tions were tested. The density of 10 nm colloidal gold particles was
determined in ten islands for each amino acid conjugate,
immunolabeling and antibody dilution (Fig. 2).
At both antibody dilutions, aspartate immunolabeling was
higher in aspartate islands compared to other amino acids
(Figs. 1B–F, 2A, B) and the differences in average density were
always significant (p,0.001, Kruskal-Wallis ANOVA on Ranks,
p,0.05 Post-hoc Dunn’s test). The density of aspartate immuno-
labeling in aspartate enriched islands varied from dense to weak
and covered a rather similar range at both antibody dilutions,
except for a few weakly labeled islands using the lower antibody
concentration (Figs. 2A,B). Average labeling density in aspartate
islands was not significantly different between antibody dilutions (t-
test, p = 0.756). However, a proportion of islands enriched with
other amino acids showed variable aspartate immunoreactivity
when the antibody was applied at high concentration. Specifically,
some glutamate enriched islands displayed aspartate immunore-
activity, however, on average, aspartate immunoreactivity in
glutamate islands was not statistically different from control blank
brain homogenates (p = 0.426, Mann-Whitney Rank Sum test).
Glutamate immunolabeling on glutamate enriched islands was
significantly higher when using the more concentrated antibody
dilution (0.17 mg/ml) compared to the least concentrated
(0.034 mg/ml) (t-test, p,0.001) (Figs. 1I, 2C,D). Also, glutamate
immunolabeling at both dilutions was always significantly higher
on glutamate enriched islands compared to any other amino acid
or blank controls (p,0.001, Kruskal-Wallis ANOVA on Ranks,
p,0.05 Pot-hoc Dunn’s test). With the exception of glutamine, all
other amino acid enriched islands were no different from blank
Figure 1. Aspartate and glutamate antibody specificity. A, Layers of amino acid enriched brain homogenates embedded between brain tissue
sections. Brain homogenate islands (arrows) contain different glutaraldehyde-fixed amino acids. Tissue sections used as spacers are all 2 mm thick
except for the last one which is 4 mm and used for sequence orientation. B–F, Gold immunolabeling of islands enriched with aspartate, GABA,
glutamate and glutamine using the aspartate antibody at 0.18 mg/ml concentration. As controls some brain homogenates were not embedded with
any amino acids (blank). Only islands embedded with aspartate (B) contained dense immunogold labeling. G–K, Immunolabeling with glutamate
antibody at 0.17 mg/ml. Islands embedded with glutamate (I) contained dense immunogold labeling. Weaker immunolabeling was observed in
glutamine islands (J). Islands embedded with aspartate (G), GABA (H) glycine (not shown) or taurine (not shown) did not contain any significant
immunogold labeling, nor did the blank or control islands lacking any amino acids (K). Scale bars, 3 mm in A; 1 mm in J.
doi:10.1371/journal.pone.0097240.g001
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controls. Glutamate-immunolabeling of glutamine islands was
significantly higher from control at both dilutions (p,0.01, Mann-
Whitney Rank Sum test). Glutamate antibodies did not show any
significant cross-reactivity with aspartate at any dilution.
In conclusion, the aspartate antibodies used here are quite
specific for glutaraldehyde-fixed aspartate, but at 0.36 mg/ml
concentration they might sometimes weakly cross-react with
glutamate. This did not occur at the 0.18 mg/ml concentration
of aspartate antibody. The glutamate antibodies in contrast, do not
recognize aspartate at the dilutions used, but they have significant
cross-reactivity with glutamine. Signal resolution was better with
0.17 mg/ml of glutamate antibody. Finally, at similar concentra-
tions of their respective specific antibodies the resulting immuno-
reactivities (particle density) were much higher for glutamate than
for aspartate.
Characteristics of VAChT and calbindin
immunoreactivities in the ventral horn
Tissue sections were dual immunolabeled in preembedding for
VAChT and calbindin. Each immunoreactivity was respectively
revealed with immunogold-silver (VAChT) or immunoperoxidase
(calbindin). Renshaw cell area regions containing both immuno-
markers were identified with light microscopy in flat embedded
preparations, re-cut with ultramicrotomy and the ultrathin
sections processed for postembedding aspartate or glutamate
colloidal gold (10 nm) immunolabeling. Silver intensified nanogold
Figure 2. Quantitative analysis of aspartate and glutamate antibody labeling in resin sandwiches. A, B, Density of labeling of amino
acid enriched islands at high (A) and low (B) aspartate antibody dilutions. Filled black dots indicate individual density estimates for each sampled
island. White circles show averaged data. Error bars indicate 6 SEM. Dotted line indicates 0 labeling. Only aspartate-enriched islands were
significantly immunolabeled above the density of blank islands (background). C, D, Similar density plots for glutamate immunolabeling at low and
high antibody dilutions. Note differences in labeling density between both antibody dilutions (different y-axis values) and also the significant labeling
of glutamine islands with glutamate antibodies.
doi:10.1371/journal.pone.0097240.g002
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VAChT immunoreactivity is recognized as relatively large and
irregularly shaped dark silver deposits (Figs. 3 and 4). These
deposits were found in cholinergic synapses contacting Renshaw
cells and at a lower density in motoneuron somata and dendrites,
as well as, at very high density in C-boutons (Fig. 4D), a particular
type of cholinergic synapse on motoneuron cell bodies [40]. The
relative density of VAChT-IR silver deposits within boutons was
maximal over vesicle pools, but the absolute density varied
depending on the depth at which the ultrathin section was
obtained within the thickness of the 50 mm immunolabeled
section. Labeling was denser at the surfaces of the section and
decreased significantly after the first 5 mm from the surface of the
tissue section. This is due to the relatively poor penetration of
antibodies in the thick sections during pre-embedding immuno-
staining using immunogold-silver techniques. Terminals with very
dense VAChT labeling were excluded from quantification, as it
was difficult to detect 10 nm colloidal gold particles within areas
containing high density silver deposits. In addition, heavily labeled
terminals were typically located near the surface of the section, an
area with usually worse tissue preservation and high background.
VAChT-IR terminals sampled deeper in the tissue section and
with weaker labeling were ideal for quantifying colloidal gold
immunolabeling.
C-boutons contacting motoneuron somata were usually char-
acterized by the presence of subsurface cisterns [36] (Fig. 4D). C-
boutons originate from interneurons [41,42] and are therefore
different from cholinergic synapses on Renshaw cells that originate
from motor axons [35]. Unfortunately, ultrastructural definition in
these non-osmicated and triple immunolabeled sections is com-
promised and the presence of subsurface cisterns underneath some
VAChT-IR boutons on motoneuron somata was sometimes
unclear. Therefore, we cannot exclude the possibility that a few
VAChT-IR synapses on motoneurons may not be C-boutons and
could originate from motor axons [43].
Calbindin-IR Renshaw cell dendritic profiles were labeled with
diaminobenzidine (DAB). Calbindin-IR was observed in Renshaw
cell somata and dendrites (Figs. 3A,C,D and 4A,B), as well as in
calbindin-IR Renshaw cell synaptic terminals (Figs. 3B, 4C). DAB
labeling appears as electron dense diffuse precipitate that is
hydrophobic and therefore becomes associated with lipid mem-
branes, such as the plasma membrane or membranes of cell
organelles. DAB labeling also diminishes with increasing depth in
the section. Moreover, DAB electron density was generally weak
in Lowicryl embedded tissue, as with cryosubstitution techniques,
osmium is not used to amplify DAB electron density. Moreover,
immunolabeling also diminished with depth within the section and
for that reason most of the sampled synapses show relatively weak
DAB labeling, with DAB precipitate deposits mainly localized to
membranes. Cryosubstituted materials were used for aspartate and
glutamate colloidal gold immunolabeling because preliminary
experiments demonstrated a higher sensitivity using this method
compared to osmicated non-cryosubstituted sections embedded in
hydrophobic resins like Epon-Araldite. These sections were
processed in parallel and displayed more electron-dense calbin-
din-immunoreactivity (not shown). Thus, we used methods that
traded strong calbindin-immunoreactivity for optimal detection of
aspartate and glutamate immunoreactivities.
Aspartate immunoreactivity
VAChT-IR terminals making synapses on calbindin-IR Re-
nshaw cells consistently displayed colloidal gold aspartate-immu-
nolabeling above neuropil staining. Aspartate-IR was observed in
the axoplasm, over synaptic vesicle pools (Figs. 3A,C,D), and over
mitochondria (see Fig. 3A inset). Sometimes we were able to
localize immunogold particles inside synaptic vesicles docked in
the presynaptic active zone (see Fig. 3D, inset), however more
commonly colloidal gold was distributed to the general area with
high numbres of synaptic vesicles being more difficult to resolve
specific relations with individual synaptic vesicles. Serial sections
through individual VAChT-IR synaptic boutons contained similar
amounts of aspartate-IR (Figs. 3C,D). Calbindin-IR Renshaw cell
dendrites and synaptic boutons (inhibitory) did not contain
aspartate-IR (Fig. 3A,B).
To quantify aspartate-IR in VAChT-IR motor axon terminals,
the area occupied by mitochondria was subtracted and colloidal
gold particles were counted only outside mitochondria. Mitochon-
drial subtraction was intended to focus the analysis to synaptic
vesicle pools and axoplasm regions from where synaptic vesicles
could directly accumulate aspartate. Synaptic vesicle immunola-
beling content could not be directly estimated because, with the
exception of some occurrences as illustrated in figure 3D inset,
indirect colloidal gold immunostaining using 10 nm particles
absorbed to IgGs lacks enough resolution to determine whether
immunoreactivities are located inside or outside synaptic vesicles
of 30 to 50 nm in diameter (immunoreactive sites are estimated to
localize within a 30 nm radius of the edge of the gold particle;
[44]).
Colloidal gold aspartate-immunolabeling was estimated using
low (0.18 mg/ml) and high (0.36 mg/ml) antibody concentrations
to better determine possible differences with neuropil labeling.
Thirty-four and 25 VAChT-IR motor axon boutons presynaptic
to calbindin-IR Renshaw cell dendrites were analyzed respectively
at each antibody concentration (Figs. 5A,B). Boutons were
sampled from tissue blocks obtained from three different animals.
Averaging the data from all boutons sampled in the three animals
resulted in a colloidal gold average density inside VAChT-IR
motor axon terminals that was significantly higher at 0.36 mg/ml
antibody concentration than at 0.18 mg/ml (21.5 particles/mm2
61.9 6SEM, vs. 13.860.2, p = 0.005, t-test) (Fig. 5E,F). Similarly,
average neuropil labeling was significantly higher at 0.36 mg/ml
antibody concentration compared to 0.18 mg/ml (9.360.6 vs.
5.560.4, p,0.001, t-test). Average aspartate immunolabeling
inside VAChT-IR motor boutons was significantly greater than on
the surrounding neuropil at both antibody dilutions and in each of
the three animals analyzed (Figs. 5C,D) (p,0.001, ANOVA, post-
hoc Tukey test p,0.001) or after combining all boutons and
background estimates from all three animals (p,0.001, t-tests at
each dilution)(Figs. 5E,F) Aspartate enrichment in VAChT-IR
motor terminals relative to neuropil (labeling in VAChT-IR motor
terminals/labeling in neuropil) was similar at both antibody
concentrations (2.86 neuropil density 60.8 SEM at 0.36 mg/ml
and 2.560.03 SEM at 0.18 mg/ml; p = 0.31, t-test).
Although enrichment in aspartate immunolabeling inside
VAChT-IR terminals compared to neuropil was detected in all
three animals, absolute values of labeling intensity varied from
animal to animal and from bouton to bouton. Inter-animal
differences sometimes reached significance at the more diluted
antibody concentration (p,0.05, ANOVA, Fig. 5D). We also
noted parallel variability among animals in basal neuropil
immunoreactivity (ANOVA, p,0.001) suggesting that the dispar-
ities are likely due to differential preservation of overall aspartate
content during fixation and processing. Despite this variability, a
similar proportion of VAChT-IR axon terminals were enriched
with aspartate immunoreactivity. Pooling together all boutons,
80% and 71% of motor axon synaptic boutons, in respectively low
and high antibody concentrations, displayed aspartate immuno-
labeling two standard deviations above the average neuropil
labeling.
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The density of aspartate-IR colloidal gold particles in VAChT-
IR terminals contacting motoneurons (C-boutons) was consistently
lower than in VAChT-IR motor axon terminals contacting
Renshaw cells in all three animals and at both antibody
concentrations (average densities in C-boutons were 9.6 parti-
cles/mm2 60.8 at high antibody concentration vs. 8.260.8 at low
concentration; differences with motor axon terminals were always
significant, p,0.001 ANOVAs, post-hoc Tukey test p,0.001)
(Fig. 5E,F). Differences between C-boutons and neuropil im-
munolabeling were generally low but reached significance at the
lower antibody concentration (8.260.8 vs. 5.560.4; p,0.001, t-
test) (Fig. 5F). This difference was however inconsistent among
samples obtained from different animals (Fig. 5D, p = 0.008 for
animal 1; p = 0.06 for animal 2 and p = 0.178 for animal 3). Only
a minority of VAChT-IR C-boutons, 17% for the low antibody
concentration and 11% for the high, contained aspartate-
immunogold density two standard deviations above their respec-
tive animal average neuropil labeling. C-boutons with aspartate
labeling at this level were frequently outliers (Fig. 5A, B). Because
of the unavoidable ultrastructural deterioration that occurs in
these non-osmicated and Lowicryl-embedded triple immunola-
beled sections, subsynaptic cisternae were not always unambigu-
ously identified. Thus, it is possible that a few VAChT-IR contacts
on motoneurons could originate from aspartate-enriched motor
axons (see above). Nevertheless, the data do allow us to conclude
that C-boutons, in general, do not contain aspartate immunola-
beling at densities significantly above the neuropil. In summary,
aspartate immunolabeling seems to be specifically enriched in
cholinergic synapses originating from motor axons.
Figure 3. Aspartate-IR is enriched in VAChT-IR boutons presynaptic to calbindin-IR Renshaw cell dendrites. These examples were
labeled with 0.18 mg/ml of aspartate antibody. A, Three VAChT-IR motoneuron terminals labeled with large and irregular immunogold-silver deposits
(irregular black particles) make synapses (arrows) with a calbindin-IR Renshaw cell dendrite labeled with DAB. Aspartate-immunogold particles (small
and uniform 10 nm size particles) are at higher density inside the three VAChT-IR synaptic boutons than in the neighboring neuropil or in the
postsynaptic Renshaw cell dendrite. Inset shows at higher magnification 10 nm colloidal gold particles (arrows) in the axoplasm (a) or a mitochondria
(m) from the area outlined in A. For comparison a silver deposit (VAChT-IR) is indicated with a big arrow. B, Aspartate-immunogold did not label
inhibitory calbindin-IR Renshaw cell synaptic terminals (white asterisk). This Renshaw cell terminal establishes a synapse (arrow) with a large dendrite
that contained a low density of aspartate-IR colloidal gold particles. A nearby synaptic bouton (black asterisk) contained a larger amount of colloidal
gold particles. C, D, VAChT-IR motoneuron synaptic boutons (a synapse with a calbindin-IR Renshaw cell dendrite is indicated with an arrow) show
similar levels of aspartate immunogold particles in serial sections (two sections in the series shown). Inset in D shows gold labeling inside a vesicle at
the presynaptic active zone (double arrow) Scale bars are 0.5 mm in A, B, C and D; 0.25 mm in the inset in A.
doi:10.1371/journal.pone.0097240.g003
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Glutamate-immunoreactivity
Glutamate-IR densities were analyzed in the same manner, also
using two antibody dilutions (0.17 mg/ml or 0.034 mg/ml) and in
tissue sections from the same three animals. Immunolabeling
above neuropil levels was noted in a portion of VAChT-IR
synapses on calbindin-IR Renshaw cell dendrites and was more
evident at the concentrated antibody dilution (Fig. 4A). Gluta-
mate-IR enrichment was also frequently observed on vesicle pools
of neighboring unlabeled Type I excitatory synapses. Inside these
synapses, glutamate-IR usually appeared more intense than in
VAChT-IR synapses (Fig. 4B). Renshaw cell inhibitory synapses
labeled with DAB did not contain glutamate-IR colloidal gold
above neuropil levels (Fig. 4C). In contrast to aspartate-IR, C-
boutons frequently contained glutamate-IR at densities above
neuropil (Fig. 4D).
Glutamate-IR colloidal gold labeling density was estimated in
31 and 36 VAChT-IR motor axon boutons at respectively high
and low antibody concentrations in tissues sampled from the same
Figure 4. Glutamate-IR is enriched in VAChT-IR motoneuron synapses contacting Renshaw cell dendrites. Examples obtained with
antibody concentration of 0.17 mg/ml. A, Three VAChT-IR boutons surround and make synapses (arrows) on a calbindin-IR Renshaw cell dendrite.
Glutamate-IR 10 nm colloidal gold particles are enriched inside VAChT-IR motoneuron terminals compared to surrounding neuropil or calbindin-IR
Renshaw dendrites. B, Glutamate-IR colloidal gold particles inside a VAChT-IR motoneuron synaptic bouton (white asterisk) making a synapse (arrow)
with a small caliber calbindin-IR Renshaw cell dendrite and an adjacent excitatory synaptic bouton (black asterisk) establishing another synapse
(arrow) on a different larger dendrite. Usually VAChT-IR synaptic boutons contain lower densities of glutamate-IR gold particles than adjacent
unlabeled terminals. C, Calbindin-IR Renshaw cell synaptic terminal (containing DAB labeling, white asterisk) making a synapse (arrow) with an
unlabeled dendrite. These inhibitory terminals contained glutamate-IR at densities similar or below neuropil labeling. A nearby VAChT-IR terminal is
making a synaptic contact (arrow) with a dendrite of unknown origin and contains higher levels of glutamate IR gold particles. D, VAChT-IR C-
boutons (silver deposits) contacting a motoneuron soma. Significant levels of glutamate -IR colloidal gold particles are found inside the C-boutons
and to a lesser extent the motoneuron cell body. These synapses have a characteristic subsynaptic cistern in the postsynaptic site (arrows). Scale bars
are 0.5 mm in A, B and C; 1 mm in D.
doi:10.1371/journal.pone.0097240.g004
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three animals (Fig. 6). Average glutamate-IR colloidal gold density
was significantly higher with the more concentrated antibody
(19.561.6 SEM compared to 10.260.9; p,0.01, Mann-Whitney
Rank Sum test) (Fig. 6E,F). Average neuropil labeling varied in
parallel with antibody concentration (9.760.7 at high antibody
concentration and 6.860.7 at low antibody concentration). At
high concentration there was some inter-animal variability in
glutamate immunolabeling of VAChT-IR motor axon terminals
or neuropil (Fig. 6C,D). Average glutamate-IR was, however,
always significantly higher in VAChT-IR motor axon terminals
compared to neuropil labeling in each animal (p,0.01, Mann-
Whitney Rank Sum tests, Fig. 6C) or when pooling data from the
three animals together (p,0.001, Mann-Whitney Rank Sum tests,
Fig. 6E). At the lower antibody concentration, inter-animal
differences in VAChT-IR motor axon terminals were not
significant (Fig. 6D, p = 0.147, Kruskal-Wallis One Way Analysis
of Variance on Ranks) but basal neuropil labeling was significantly
different between animals (p,0.001 Kruskal-Wallis One Way
Analysis of Variance on Ranks; p,0.05, post-hoc Dunn test for
pair-wise comparisons). Pooled data from all three animals
indicated that glutamate-IR inside VAChT-IR terminals was
significantly higher than neuropil labeling even in low labeling
conditions (p,0,001, Mann-Whitney Rank Sum test). At high and
low antibody concentrations, average bouton labeling was
respectively 2.060.2 and 1.760.5 times the neuropil staining.
The enrichment values calculated at different antibody concen-
trations were not statistically significant (t-test, p = 0.214). Labeling
was therefore consistently higher than neuropil, but average
glutamate-IR enrichment from neuropil basal level was not as high
as with aspartate immunolabeling. Analysis of scatter plots
(Fig. 6A,B) suggests this was due to the presence of a large
proportion of synapses with no labeling above neuropil in both
high and low antibody dilutions. Consequently, only 44% and
21% of VAChT-IR motor axon terminals showed glutamate-IR
two standard deviations above average neuropil labeling at high
and low antibody concentrations respectively.
Compared to aspartate labeling, C-boutons were more consis-
tently immunolabeled with glutamate antibodies. C-boutons
displayed an average immunolabeling density significantly higher
than neuropil at both glutamate antibody concentrations. Differ-
ences with neuropil labeling were always significant when making
comparisons within animals (p,0.001 ANOVA, post-hoc Tukey
tests p,0.05) or when pooling data from the three animals
together (p,0.001, t-test). C-bouton glutamate labeling was
similar to motor axon terminals at high antibody concentrations
and even significantly higher at low antibody concentrations.
Average enrichment levels from neuropil were similar at both
dilutions (2.160.2 at the highest concentration of antibody and
2.260.3 at the lowest). About half of the C-boutons contained an
immunolabeling density higher than two standard deviations from
average neuropil labeling (54.5% at the highest antibody dilution,
45% at the lowest; n = 22 C-boutons analyzed at each dilution). In
conclusion, glutamate is enriched with respect to neuropil in some
VAChT-IR motor axons and C-boutons.
Discussion
The major finding in this study is that motor axon synapses on
Renshaw cells are enriched in both aspartate and glutamate, but at
different levels. Aspartate was detected at 2.5 to 2.8 times
background level and was consistently 2 standard deviations
higher than the neuropil average in the majority of the terminals.
Enrichment in glutamate immunoreactivity above 2 standard
deviations of neuropil labeling was found in less than half of motor
axon synapses on Renshaw cells and on average they contained
1.7 to 2 times the background levels. The average level of
glutamate enrichment was similar to previous estimates using
confocal microscopy [17]. From these data we conclude that
aspartate is more highly enriched than glutamate in motor axon
synapses on Renshaw cells.
Mechanisms for the accumulation of glutamate and
aspartate inside synaptic vesicles
The fact that aspartate and glutamate immunoreactivities are
enriched in areas within synaptic boutons containing high density
of synaptic vesicles, including presynaptic active zones, suggests
that these amino acids could be accumulated in a releasable pool.
In all of our analyses we substracted mitochondrial labeling to
focus the study on potentially releasable pools of EAAs. A high
immunoreactivity content in mitochondria of glutamate and
aspartate, even also GABA, is well-known at many central
synapses [37,45,46,47]. They are best explained by their function
as intermediate metabolites and their synthesis and storage during
mitochondrial function, oxidative metabolism and the glutamine-
glutamate-GABA cycle [48]. Since is unlikely that EAA mito-
chondrial content directly contributes to the releasable pools of
these aminoacids, mitochondrial immunolabeling was not includ-
ed in the estimates.
The exact mechanisms by which glutamate and aspartate are
introduced inside motor axon synaptic vesicles remains unclear.
The relatively lower levels of glutamate might agree with low
expression of VGLUT2, but as reviewed in the introduction, the
presence of VGLUT2 in motor axon terminals is at present not
clear, with contradictory conclusions in current literature
[17,18,20,21]. All studies agree, however, that VGLUT2 and
VAChT do not co-localize within intraspinal motor axon synaptic
terminals, raising the possibility that cholinergic and ‘‘glutamater-
gic’’ motor axon synapses originate from either different moto-
neurons or different motor axon collaterals, as originally proposed
by Herzog et al. [20]. The first possibility is highly unlikely because
Figure 5. Quantification of aspartate-IR revealed enrichment over VAChT-IR motoneuron terminals contacting calbindin-IR
Renshaw cells. A, B, Aspartate-IR gold densities in VAChT-IR boutons (on Renshaw cells or on motoneurons) and neuropil at antibody
concentrations of 0.36 mg/ml (A) or 0.18 mg/ml (B). Estimates are separated according to animal sampled in A to D and pooled together for all animals
in E and F. Each neuropil estimate is from an individual micrograph (2 to 4 areas analyzed per negative). The numbers of boutons or neuropil
estimates are indicated above the respective plots. VAChT-IR boutons on Renshaw cells display aspartate-immunolabeling densities frequently higher
than neuropil. VAChT-IR terminals contacting motoneurons contain immunolabeling densities usually similar to neuropil. C, D, Histograms showing
average densities at high (C) or low (D) antibody concentrations for each type of terminal and neuropil in each animal. Error bars indicate 6 SEM. At
both antibody dilutions average aspartate-IR density in VAChT-IR boutons on Renshaw cells was consistently higher than neuropil averages or over
VAChT-IR terminals contacting motoneurons. Variability among animals reached significance in two occasions using the low antibody concentration
(asterisks in C and D; ANOVA, p,0.001 and post-hoc Tukey Test). E, F, Histograms representing pooled averages from all boutons sampled in the 3
animals at high (E) or low (F) antibody concentrations. Error bars also indicate 6 SEM. At both dilutions the average density of aspartate-IR was
significantly higher in VAChT-IR terminals contacting calbindin-IR Renshaw cells than in the neuropil or over VAChT-IR terminals contacting
motoneurons (asterisks, p,0.001 ANOVA and post-hoc Tukey Tests). At the low antibody dilution C-boutons showed aspartate immunolabeling
slightly above neuropil.
doi:10.1371/journal.pone.0097240.g005
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to our knowledge there are no non-cholinergic motoneuron
phenotypes in the mammalian spinal cord. The second possibility
will be an interesting exception to Dale’s principle, but our data
argue against it because we found significant enrichment of
glutamate and aspartate inside VAChT-IR terminals. It is possible
that by using VAChT immunoreactivity as the identification
criterion, we might have missed a population of VAChT negative
motor axon synaptic boutons more highly enriched in glutamate.
However, we find this possibility also unlikely because bulk
retrograde labeling of motor axons from ventral roots consistently
failed to reveal motor axon synaptic varicosities lacking VAChT-
immunoreactivity [17]. Present conclusions for motor axon
synapses that are VGLUT2 positive and VAChT negative is based
on two intracellular fills of motoneurons and their putative motor
axons [18,20]. A third study was not able to confirm this
conclusion [21]. Differences in species and age (neonatal rodents
vs. adult cats) might explain the discrepancy; but unfortunately the
axonal nature of VGLUT2-IR structures in the two earlier studies
was not fully established. Better and more complete labeling of
motor axons and their intraspinal synapses would be necessary to
unequivocally support the conclusion that different collaterals
from single motor axons traffic distinct synaptic release machinery
to different synaptic boutons.
An alternative possibility is that glutamate transport inside
synaptic vesicles is mediated by a different protein, perhaps less
efficient than VGLUTs. In addition, none of the known VGLUTs
transport aspartate [26,31,32,34], and therefore a transporter
mechanism capable of carrying aspartate inside synaptic vesicles
needs to be established for motoneurons. VGLUTs belong to the
SLC17 family, members of this family include several Na+/
phosphate co-transporters (SLC17A1-4), a lysosomal H+/sialic
acid co-transporter (SLC17A5), the three VGLUTs (SLC17A6-8)
and a vesicular nucleotide transporter (VNUTs) (SLC17A9) [49].
SLC17A5 was initially related to the transport of sialic acid in
lysosomal membranes and associated with sialic acid storage
hereditary diseases like Salla disease [50]. Its high amino acid
sequence homology with VGLUTs (SLC17A6-8) led to SLC17A5
being tested as a possible aspartate transporter. The study of
Miyaji et al., [51] concluded that SLC17A5 moves both aspartate
and glutamate into synaptic vesicles of hippocampal synapses and
pinealocytes, both known to release aspartate. However, a more
recent study using SLC17A5 knockout animals demonstrated
SLC17A5-independent uptake and release of aspartate in synap-
tosomal fractions and hippocampal synapses [33]. The levels of
uptake and release of aspartate were unaltered in animals lacking
SLC17A5, suggesting that loading of aspartate inside synaptic
vesicles occurs using transporter mechanisms different from
SLC17A5.
In agreement with these later results we failed to detect
SLC17A5 immunoreactivity inside VAChT-IR synapses on
Renshaw cells using three different commercial antibodies. These
data were not presented in results because of doubts about the
specificity of all the immunoreactivites detected by these antibodies
in spinal cord sections. Each antibody was raised against different
epitopes of the protein. One antibody was obtained from Abcam
(cat#ab69819; lots# 598964, 827317; Cambrige, MA, USA) and
was raised against amino acids 151 to 200 expanding regions in
cytosolic and non-cytosolic regions of the molecule flanking the
putative 4th transmembrane domain. This region has 90%
homology with amino acids 125 to 174 in the mouse sequence.
The antibody obtained from Alpha Diagnostic International
(cat.#SIAL11-A; lot# 4831P2; San Antonio, TX, USA) was
raised against amino acids 84 to 99 in the first putative non-
cytosolic domain between transmembrane regions 1 and 2 (i.e.,
extracellular if inserted in the plasma membrane or facing the
lumen if inserted in the membrane of lysosomes or other
cytoplasmic organelles). This region has a 93% identity with
amino acids 54 to 68 in mouse SLC17A5. Finally, we also used an
antibody obtained from Santa Cruz (V-18, SC50977; lot J2209)
raised against a peptide (exact sequence proprietary Santa Cruz
information) that is contained within amino acids 70 to 190 in the
N-terminal. This antibody also resulted in the weakest immuno-
labeling of spinal cord sections. All three antibodies recognized
SLC17A5 in heterologous expression systems, as indicated by
manufacturer information. But in Western blots from spinal cord,
in our hands, all three antibodies detected a band around the 51 to
60 kDa expected molecular weight of SLC17A5 and also several
additional immunoreactive bands of higher and lower molecular
weights (not shown). These were consistently present in many
different conditions (denaturing, gel gradients, deglycosylation,
protease inhibitor cocktails). Moreover, the immunoreactivities in
spinal cord sections were different between all three antibodies. It
is possible that all three antibodies are capable of immunodetect-
ing SLC17A5, but each displays either different cross-reactivities
with other proteins in tissue, or might detect SLC17A5 in different
compartments depending on differential exposure or masking of
their different epitopes. Similar specificity concerns with these
antibodies were recently raised in another study [33]. Therefore,
these antibodies rendered ‘‘dirty’’ immunoreactions in the spinal
cord and require further investigation before the exact nature of
SLC17A5 immunoreactivity can be reported with confidence.
Nevertheless, we quantified the possible presence of SLC17A5
immunofluorescence in 131, 101 and 93 VAChT-IR synapses on
calbindin-IR Renshaw cell dendrites with respectively the AbCam,
Alpha Diagnostic and Santa Cruz antibodies. In only two cases we
detected small immunofluorescence peaks inside VAChT-IR
synapses that were above neuropil labeling. These results suggest
that it is unlikely that SLC17A5 is present in motor axon synapses,
but this conclusion needs to be confirmed with further antibodies
that show better specificity and sensitivity of immunodetection in
tissue. The transporter mechanism that accumulates aspartate,
Figure 6. Quantification of glutamate-IR inside VAChT-IR motoneuron terminals contacting calbindin-IR Renshaw cells and C-
boutons. A, B, Dot blots showing colloidal gold immunolabeling densities at high (A) or low (B) glutamate antibody concentrations in individual
VAChT-IR motoneuron terminals contacting calbindin-IR Renshaw cells, in C-boutons (VAChT-IR terminals on motoneurons) and in the neuropil of the
three experimental animals. C, D, Average density of glutamate-IR in each type of synaptic bouton and in the neuropil for each antibody
concentration and animal analyzed. Inter-animal variability in glutamate immunolabeling of VAChT-IR motor axon or C-boutons and in neuropil
labeling estimates was relatively low using the high antibody concentration (C) but increased when using the low antibody concentration (D).
Asterisks indicate significant differences. E, F, Pooled data average histograms from the 3 mice using glutamate antibodies at 0.17 mg/ml (E) and
0.034 mg/ml (F). Glutamate-IR in VAChT-IR terminals contacting calbindin-IR Renshaw cell dendrites was significantly higher compared to neuropil at
both antibody dilutions (asterisk indicate p,0.001, ANOVA and p,0.05 post-hoc pair-wise comparisons using a Tukey test). C-boutons showed
immunolabeling density similar to VAChT-IR motor axon terminals at high antibody dilutions but significantly higher glutamate immunolabeling
density compared to neuropil with low antibody concentrations. In both cases they contained significantly higher colloidal gold densities than the
neuropil.
doi:10.1371/journal.pone.0097240.g006
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and maybe glutamate, inside synaptic vesicles in motor axons is
therefore not yet settled and requires further investigation.
Functional significance
Independent of the exact transport mechanism introducing
aspartate and/or glutamate inside vesicles, motor axon evoked
EPSPs and EPSCs in Renshaw cells display simultaneous
postsynaptic activation of nicotinic, AMPA and NMDA receptors
[15–18]. While NMDA receptors can be equally activated by
released aspartate or glutamate, AMPA receptors can only be
activated by glutamate and perhaps the low levels of glutamate
inside motor axon boutons explains the smaller and more variable
characteristics of AMPAergic currents at this synapse [15]. Thus,
motor axon synapses on Renshaw cells can be considered to
operate principally as nicotinic/NMDA synapses lacking strong
AMPA currents, which implies that the nicotinic current is the
principal mechanism removing the voltage-dependent Mg2+ block
of the NMDA receptor [15,16]. The necessity of close spatial and
temporal activation of nicotinic and NMDA receptors therefore
also argues against an organization in which different motor axon
collaterals independently release acetylcholine and EAAs. Indeed,
to increase the efficiency of NMDA activation it would be optimal
if all neurotransmitters were co-released from the same vesicles;
unfortunately, synaptic vesicle content could not be directly
estimated because indirect colloidal gold immunostaining using
10 nm particles absorbed to IgGs lacks enough resolution to
determine whether immunoreactivities are located inside or
outside synaptic vesicles of 30 to 50 nm in diameter (immunore-
active sites are estimated to localize within a 30 nm radius of the
edge of the gold particle [44]). Single vesicle co-release of
glutamate and acetylcholine has been demonstrated from inter-
neuron synapses in the tadpole spinal cord [52]. However, a recent
preliminary report suggests that this is not the situation at motor
axon synapses on Renshaw cells and concludes that acetylcholine
and EAAs are released by different pools of synaptic vesicles [53].
If confirmed, this organization implies the need for synchronous
‘‘multiquantal’’ release to obtain a close spatial and temporal
postsynaptic activation of nicotinic and NMDA receptors. Multi-
quantal release could occur from a single bouton or from adjacent
boutons. The structure of the motor axon input on Renshaw cells
could facilitate the latter interaction because single motor axon
collaterals form several adjacent ‘‘en passant’’ synapses on small
dendrite segments [54] and ultrastruturally is common to find
many closely spaced synapses (see Figures 3A and 5A). This
synaptic architecture, coupled with the fact that neurotransmitter
spill-over at these synapses is common [16], could facilitate
effective co-activation of nicotinic and NMDA receptors, even if
the cognate neurotransmitters are released at different but closely-
spaced synapses along single axon collateral branches.
The possibility that aspartate actions on NMDA receptors are
responsible for a significant share of non-cholinergic effects of
motoneurons inside the spinal cord implies that aspartate
responsive interneurons expressing NMDA receptors will be
preferentially targeted. One example is the elongation of Renshaw
cell firing in response to motor axon inputs through NMDA-
dependent mechanisms blocked by APV [15]. Another is the
ability of ventral roots to activate the spinal cord Central Pattern
Generator (CPG) and elicit rhythmic activity also through an APV
sensitive mechanism [17]. This does not exclude additional actions
of motor axon released glutamate since AMPA activation also
occurs on Renshaw cells and more recent data suggest that
entrainment of the spinal CPG by ventral root stimulation is
sensitive to antagonists specific of AMPA activation of mGluR1
metabotropic glutamate receptors [55].
In conclusion, the immunocytochemical data presented here is
consistent with the notion that motoneuron intraspinal synapses
release acetylcholine, aspartate and to lesser extent glutamate and
this fits with the pharmacological profiles of known synaptic
actions of motor axons on Renshaw cells and the spinal cord
network in general.
Acknowledgments
The authors wish to thank Mr. Ricardo Zerda for help with immunoelec-
tron techniques, Dr. George Z. Mentis (Columbia University) for helpful
comments on the manuscript, Dr. Ole P. Ottersen (University of Oslo) for
sharing the control embedded sandwiches.
Author Contributions
Conceived and designed the experiments: FJA. Performed the experiments:
DR RG SR. Analyzed the data: DR RG SR. Wrote the paper: FJA.
References
1. Dale HH, Feldberg W, Vogt M (1936) Release of acetylcholine at voluntary
motor nerve endings. J Physiol 86: 353–380.
2. Mays TA, Sanford JL, Hanada T, Chishti AH, Rafael-Fortney JA (2009)
Glutamate receptors localize postsynaptically at neuromuscular junctions in
mice. Muscle & Nerve 39: 343–349.
3. Rinholm JE, Slettalokken G, Marcaggi P, Skare O, Storm-Mathisen J, et al.
(2007) Subcellular localization of the glutamate transporters GLAST and GLT
at the neuromuscular junction in rodents. Neuroscience 145: 579–591.
4. Waerhaug O, Ottersen OP (1993) Demonstration of glutamate-like immuno-
reactivity at rat neuromuscular junctions by quantitative electron microscopic
immunocytochemistry. Anat and Embryol 188: 501–513.
5. Malomouzh AI, Mukhtarov MR, Nikolsky EE, Vyskocil F, Lieberman EM, et al.
(2003) Glutamate regulation of non-quantal release of acetylcholine in the rat
neuromuscular junction. J Neurochem 85: 206–213.
6. Pinard A, Levesque S, Vallee J, Robitaille R (2003) Glutamatergic modulation of
synaptic plasticity at a PNS vertebrate cholinergic synapse. Eur J Neurosci 18:
3241–3250.
7. Petrov KA, Malomouzh AI, Kovyazina IV, Krejci E, Nikitashina AD, et al.
(2013) Regulation of acetylcholinesterase activity by nitric oxide in rat
neuromuscular junction via N-methyl-D-aspartate receptor activation.
Eur J Neurosci 37: 181–189.
8. Brunelli G, Spano P, Barlati S, Guarneri B, Barbon A, et al. (2005)
Glutamatergic reinnervation through peripheral nerve graft dictates assembly
of glutamatergic synapses at rat skeletal muscle. Proc Nat Acad Sci USA 102:
8752–8757.
9. Pizzi M, Brunelli G, Barlati S, Spano P (2006) Glutamatergic innervation of rat
skeletal muscle by supraspinal neurons: a new paradigm in spinal cord injury
repair. Curr. Opinion Neurobiol. 16: 323–328.
10. Eccles JC, Fatt P, Koketsu K (1954) Cholinergic and inhibitory synapses in a
pathway from motor-axon collaterals to motoneurones. J Physiol 126: 524–562.
11. Renshaw B (1946) Central effects of centripetal impulses in axons of spinal
ventral roots. J Neurophysiol 9: 191–204.
12. Eccles JC, Eccles RM, Iggo A, Lundberg A (1961) Electrophysiological
investigations on Renshaw cells. J Physiol 159: 461–478.
13. Dourado M, Sargent PB (2002) Properties of nicotinic receptors underlying
Renshaw cell excitation by alpha-motor neurons in neonatal rat spinal cord.
J Neurophysiol 87: 3117–3125.
14. Schneider SP, Fyffe RE (1992) Involvement of GABA and glycine in recurrent
inhibition of spinal motoneurons. J Neurophysiol 68: 397–406.
15. Lamotte d’Incamps B, Ascher P (2008) Four excitatory postsynaptic ionotropic
receptors coactivated at the motoneuron-Renshaw cell synapse. J Neurosci 28:
14121–14131.
16. Lamotte d’Incamps B, Krejci E, Ascher P (2012) Mechanisms shaping the slow
nicotinic synaptic current at the motoneuron-renshaw cell synapse. J Neurosci
32: 8413–8423.
17. Mentis GZ, Alvarez FJ, Bonnot A, Richards DS, Gonzalez-Forero D, et al.
(2005) Noncholinergic excitatory actions of motoneurons in the neonatal
mammalian spinal cord. Proc. Nat. Acad. Sci. USA 102: 7344–7349.
18. Nishimaru H, Restrepo CE, Ryge J, Yanagawa Y, Kiehn O (2005) Mammalian
motor neurons corelease glutamate and acetylcholine at central synapses. Proc
Nat Acad Sci USA 102: 5245–5249.
Motor Axon Aspartate and Glutamate Content
PLOS ONE | www.plosone.org 13 May 2014 | Volume 9 | Issue 5 | e97240
19. Walmsley B, Tracey DJ (1981) An intracellular study of Renshaw cells. Brain
Res 223: 170–175.
20. Herzog E, Landry M, Buhler E, Bouali-Benazzouz R, Legay C, et al. (2004)
Expression of vesicular glutamate transporters, VGLUT1 and VGLUT2, in
cholinergic spinal motoneurons. Eur J Neurosci 20: 1752–1760.
21. Liu TT, Bannatyne BA, Jankowska E, Maxwell DJ (2009) Cholinergic terminals
in the ventral horn of adult rat and cat: evidence that glutamate is a
cotransmitter at putative interneuron synapses but not at central synapses of
motoneurons. Neuroscience 161: 111–122.
22. Landry M, Bouali-Benazzouz R, El Mestikawy S, Ravassard P, Nagy F (2004)
Expression of vesicular glutamate transporters in rat lumbar spinal cord, with a
note on dorsal root ganglia. J Comp Neurol 468: 380–394.
23. Kullander K, Butt SJ, Lebret JM, Lundfald L, Restrepo CE, et al. (2003) Role of
EphA4 and EphrinB3 in local neuronal circuits that control walking. Science
299: 1889–1892.
24. Llewellyn-Smith IJ, Martin CL, Fenwick NM, Dicarlo SE, Lujan HL, et al.
(2007) VGLUT1 and VGLUT2 innervation in autonomic regions of intact and
transected rat spinal cord. J Comp Neurol 503: 741–767.
25. Oliveira AL, Hydling F, Olsson E, Shi T, Edwards RH, et al. (2003) Cellular
localization of three vesicular glutamate transporter mRNAs and proteins in rat
spinal cord and dorsal root ganglia. Synapse 50: 117–129.
26. Fremeau RT, Jr., Burman J, Qureshi T, Tran CH, Proctor J, et al. (2002) The
identification of vesicular glutamate transporter 3 suggests novel modes of
signaling by glutamate. Proc Nat Acad Sci USA 99: 14488–14493.
27. Takamori S, Rhee JS, Rosenmund C, Jahn R (2000) Identification of a vesicular
glutamate transporter that defines a glutamatergic phenotype in neurons. Nature
407: 189–194.
28. Wojcik SM, Rhee JS, Herzog E, Sigler A, Jahn R, et al. (2004) An essential role
for vesicular glutamate transporter 1 (VGLUT1) in postnatal development and
control of quantal size. Proc Nat Acad Sci USA 101: 7158–7163.
29. Moechars D, Weston MC, Leo S, Callaerts-Vegh Z, Goris I, et al. (2006)
Vesicular glutamate transporter VGLUT2 expression levels control quantal size
and neuropathic pain. The J Neurosci 26: 12055–12066.
30. Curras MC, Dingledine R (1992) Selectivity of amino acid transmitters acting at
N-methyl-D-aspartate and amino-3-hydroxy-5-methyl-4-isoxazolepropionate
receptors. Mol. Pharm. 41: 520–526.
31. Bellocchio EE, Reimer RJ, Fremeau RT, Jr., Edwards RH (2000) Uptake of
glutamate into synaptic vesicles by an inorganic phosphate transporter. Science
289: 957–960.
32. Herzog E, Bellenchi GC, Gras C, Bernard V, Ravassard P, et al. (2001) The
existence of a second vesicular glutamate transporter specifies subpopulations of
glutamatergic neurons. J Neurosci 21: RC181.
33. Morland C, Nordengen K, Larsson M, Prolo LM, Farzampour Z, et al. (2013)
Vesicular uptake and exocytosis of L-aspartate is independent of sialin. FASEB
journal 27: 1264–1274.
34. Varoqui H, Schafer MK, Zhu H, Weihe E, Erickson JD (2002) Identification of
the differentiation-associated Na+/PI transporter as a novel vesicular glutamate
transporter expressed in a distinct set of glutamatergic synapses. J Neurosci 22:
142–155.
35. Siembab VC, Smith CA, Zagoraiou L, Berrocal MC, Mentis GZ, et al. (2010)
Target selection of proprioceptive and motor axon synapses on neonatal V1-
derived Ia inhibitory interneurons and Renshaw cells. J Comp Neurol 518:
4675–4701.
36. Conradi S (1969) On motoneuron synaptology in adult cats. Acta Physiol.
Scand. 332: 5–48.
37. Ottersen OP (1987) Postembedding light- and electron microscopic immuno-
cytochemistry of amino acids: description of a new model system allowing
identical conditions for specificity testing and tissue processing. Exp Brain Res
69: 167–174.
38. Wootz H, Fitzsimons-Kantamneni E, Larhammar M, Rotterman TM, Enjin A,
et al. (2013) Alterations in the motor neuron-renshaw cell circuit in the
Sod1(G93A) mouse model. J Comp Neurol 521: 1449–1469.
39. Celio MR (1990) Calbindin D-28k and parvalbumin in the rat nervous system.
Neuroscience 35: 375–475.
40. Connaughton M, Priestley JV, Sofroniew MV, Eckenstein F, Cuello AC (1986)
Inputs to motoneurones in the hypoglossal nucleus of the rat: light and electron
microscopic immunocytochemistry for choline acetyltransferase, substance P
and enkephalins using monoclonal antibodies. Neuroscience 17: 205–224.
41. Miles GB, Hartley R, Todd AJ, Brownstone RM (2007) Spinal cholinergic
interneurons regulate the excitability of motoneurons during locomotion. Proc
Nat Acad Sci USA 104: 2448–2453.
42. Zagoraiou L, Akay T, Martin JF, Brownstone RM, Jessell TM, et al. (2009) A
cluster of cholinergic premotor interneurons modulates mouse locomotor
activity. Neuron 64: 645–662.
43. Lagerback PA, Ronnevi LO, Cullheim S, Kellerth JO (1981) An ultrastructural
study of the synaptic contacts of alpha-motoneurone axon collaterals. I. Contacts
in lamina IX and with identified alpha-motoneurone dendrites in lamina VII.
Brain Res 207: 247–266.
44. Matsubara A, Laake JH, Davanger S, Usami S, Ottersen OP (1996)
Organization of AMPA receptor subunits at a glutamate synapse: a quantitative
immunogold analysis of hair cell synapses in the rat organ of Corti. J Neurosci
16: 4457–4467.45. Ottersen OP (1989) Quantitative electron microscopic
immunocytochemistry of neuroactive amino acids. Anatomy and embryology
180: 1–15.
45. Shupliakov O, Atwood HL, Ottersen OP, Storm-Mathisen J, Brodin L (1995)
Presynaptic glutamate levels in tonic and phasic motor axons correlate with
properties of synaptic release. The Journal of neuroscience: the official journal of
the Society for Neuroscience 15: 7168–7180.
46. Gundersen V, Chaudhry FA, Bjaalie JG, Fonnum F, Ottersen OP, et al. (1998)
Synaptic vesicular localization and exocytosis of L-aspartate in excitatory nerve
terminals: a quantitative immunogold analysis in rat hippocampus. The Journal
of neuroscience: the official journal of the Society for Neuroscience 18: 6059–
6070.
47. Hertz L (2013) The Glutamate-Glutamine (GABA) Cycle: Importance of Late
Postnatal Development and Potential Reciprocal Interactions between Biosyn-
thesis and Degradation. Frontiers in endocrinology 4: 59.
48. Reimer RJ, Edwards RH (2004) Organic anion transport is the primary function
of the SLC17/type I phosphate transporter family. Pflugers Archiv 447: 629–
635.
49. Verheijen FW, Verbeek E, Aula N, Beerens CE, Havelaar AC, et al. (1999) A
new gene, encoding an anion transporter, is mutated in sialic acid storage
diseases. Nature Genetics 23: 462–465.
50. Miyaji T, Echigo N, Hiasa M, Senoh S, Omote H, et al. (2008) Identification of
a vesicular aspartate transporter. Proc Nat Acad Sci USA 105: 11720–11724.
51. Li WC, Soffe SR, Roberts A (2004) Glutamate and acetylcholine corelease at
developing synapses. Proc Nat Acad Sci USA 101: 15488–15493.
52. Lamotte d’Incamps B, Ascher P (2013) Glutamatergic and cholinergic miniature
synaptic currents at the motoneuron-Renshaw cell synapse. Program
No. 229.27. 2011 Neuroscience Meeting Planner. Washington, DC: Society
for Neuroscience, 2011. Online.
53. Alvarez FJ, Dewey DE, McMillin P, Fyffe RE (1999) Distribution of cholinergic
contacts on Renshaw cells in the rat spinal cord: a light microscopic study. J.
Physiol 515: 787–797.
54. Bonnot A, Chub N, Pujala A, O’Donovan MJ (2009) Excitatory actions of
ventral root stimulation during network activity generated by the disinhibited
neonatal mouse spinal cord. J Neurophysiol 101: 2995–3011.
Motor Axon Aspartate and Glutamate Content
PLOS ONE | www.plosone.org 14 May 2014 | Volume 9 | Issue 5 | e97240
